Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
02 October 2014Website:
http://www.citiuspharma.comNext earnings report:
14 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:57:10 GMTDividend
Analysts recommendations
Institutional Ownership
CTXR Latest News
Management call scheduled for Monday, June 3, 2024 at 8:30 AM ET CRANFORD, N.J. , May 29, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it will host an investor call on Monday, June 3, 2024 at 8:30 am ET to discuss the topline results of its Phase 3 Trial of Mino-Lok antibiotic lock solution.
Citius Pharma recently released its second quarter 2024 results, reporting earnings per share of -5 cents.
The article provides an updated analysis of Citius Pharmaceuticals following a previous piece in February 2023. Citius' lead therapy has a midsummer 2023 PDUFA; it has generated excitement among investors, although it is unlikely to generate alpha. Its second lead therapy is likely to disappoint.
What type of business is Citius Pharmaceuticals?
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
What sector is Citius Pharmaceuticals in?
Citius Pharmaceuticals is in the Healthcare sector
What industry is Citius Pharmaceuticals in?
Citius Pharmaceuticals is in the Biotechnology industry
What country is Citius Pharmaceuticals from?
Citius Pharmaceuticals is headquartered in United States
When did Citius Pharmaceuticals go public?
Citius Pharmaceuticals initial public offering (IPO) was on 02 October 2014
What is Citius Pharmaceuticals website?
https://www.citiuspharma.com
Is Citius Pharmaceuticals in the S&P 500?
No, Citius Pharmaceuticals is not included in the S&P 500 index
Is Citius Pharmaceuticals in the NASDAQ 100?
No, Citius Pharmaceuticals is not included in the NASDAQ 100 index
Is Citius Pharmaceuticals in the Dow Jones?
No, Citius Pharmaceuticals is not included in the Dow Jones index
When does Citius Pharmaceuticals report earnings?
The next expected earnings date for Citius Pharmaceuticals is 14 August 2024